The Wnt Signaling Pathway and Related Therapeutic Drugs in Autism Spectrum Disorder.
10.9758/cpn.2018.16.2.129
- Author:
Seung Min BAE
1
;
Ji Yeon HONG
Author Information
1. Department of Psychiatry, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. manitch@hanmail.net
- Publication Type:Review
- Keywords:
Autism spectrum disorder;
Wnt;
Beta-catenin;
Chromodomain helicase DNA binding protein 8;
Neuronal development
- MeSH:
Autism Spectrum Disorder*;
Autistic Disorder*;
beta Catenin;
Chromatin Assembly and Disassembly;
Neurodevelopmental Disorders;
Wnt Signaling Pathway*
- From:Clinical Psychopharmacology and Neuroscience
2018;16(2):129-135
- CountryRepublic of Korea
- Language:English
-
Abstract:
Autism spectrum disorder (ASD) is a series of neurodevelopmental disorder with a large genetic component. However, the pathogenic genes and molecular mechanisms of ASD have not been clearly defined. Recent technological advancements, such as next-generation sequencing, have led to the identification of certain loci that is responsible for the pathophysiology of ASD. Three functional pathways, such as chromatin remodeling, Wnt signaling and mitochondrial dysfunction are potentially involved in ASD. In this review, we will focus on recent studies of the involvement of Wnt signaling pathway components in ASD pathophysiology and related drugs used in ASD treatment.
